Stock Analiz

Aspire-Lakewood Holdings, Inc. ASBP

Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026

$8.41Market cap $12M
Open the interactive analysis →

Aspire-Lakewood Holdings, Inc. (ASBP) is a healthcare company listed in the US with a market value of about $12M. In the twelve months to June 30, 2026 it had revenue of $97659 and net income of -$11M, a net margin of -11314.1%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

About Aspire-Lakewood

Aspire-Lakewood is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2022. It was profitable in 2 of the last 4 years in our data. It spends 14897% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S120.8
P/B1.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-60.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-394700.0%
ROIC (5-yr avg.)—
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 4 years

Fiscal yearTTM2025202420232022
Revenue$97659$6202———
Net income-$11M-$24M-$1M$4M$3M
Free cash flow-$7M-$5M-$265186——
EPS (diluted)$-7.39$-16.38$-1.90——
Net margin-11314.1%-394700.0%———
ROIC—————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Aspire-Lakewood pay a dividend?

Not currently.

Is Aspire-Lakewood a good stock to buy?

We do not give buy or sell advice. Aspire-Lakewood scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.